James C. Ulchaker, MD, shares his insights on the current range of BPH therapies.

Jared S. Winoker, MD, addresses the wide range of stone burdens treated by the CVAC system for the study.

The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.

The committee voted 4-5 in opposition of a favorable benefit-risk profile.

Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.

The phase 3 study design will now be submitted for final review by the agency.

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

The bladder transplant procedure involved a collaboration between the University of California, Los Angeles and the University of Southern California.

"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.

Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.

Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.

The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.

Professor Andreas Skolarikos shares his experience with the LithoVue Elite System.

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.

ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.

The freedom from re-intervention rate was 71%.

Use of focal therapy was shown to prolong the duration of active surveillance.

"I’m hopeful because women in urology are no longer an exception—they’re becoming the norm," says Shaya Taghechian, MD.

The phase 3 RC48-C016 trial met its primary end points.

Urologist Garrett D. Pohlman, MD, reflects on the benign prostatic hyperplasia offerings from the 2025 American Urological Association Annual Meeting.

The data are to be presented at an upcoming medical conference.

"This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.

Patient-reported pain scores were significantly improved with stent omission.

“We do not feel that our results undermine the importance of fluid intake for stone prevention," says Alana C. Desai, MD.